85 results about "Immuno suppression" patented technology

The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are characterized in that the expression of beta 2-microglobulin (B2M) and / or class II major histocompatibility complex transactivator (CIITA) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding B2M and / or CIITA, or by using nucleic acid molecules which inhibit the expression of B2M and / or CIITA. In order to further render the T-cell non-alloreactive, at least one gene encoding a component of the T-cell receptor is inactivated, e.g., by using a rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding said TCR component. In addition, expression of immunosuppressive polypeptide can be performed on those modified T-cells in order to prolong the survival of these modified T cells in host organism. Such modified T-cell is particularly suitable for allogeneic transplantations, especially because it reduces both the risk of rejection by the host's immune system and the risk of developing graft versus host disease. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer, infections and auto-immune diseases.

The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed.

The invention relates to the technical field of mesenchymal stem cells for cell therapy, in particular to a method for strengthening an immune-suppression function of the mesenchymal stem cells. Separated mesenchymal stem cells are sub-cultured and then cultured in a culture medium containing IFN-gamma, IL-1beta and progesterone. After subjected to co-cultivation and activation of the IFN-gamma, theIL-1beta and the progesterone, the suppression ratio of the MSC cells to lymphocyte proliferation is improved by 2-7 times, the expression of immune-suppression protein in the MSC cells is improved by 2-12 times, the capacity of cell secretion anti-inflammatory cytokines is improved by 5-20 times, and the capacity of secretion proinflammatory cytokines is reduced by 10%-30%, and the immune-suppression activity of the MSC cells is increased greatly.

Apparatus and methods are disclosed for treating allergic rhinitis (seasonal and perennial hay fever), by application of flash lamp radiation. The nasal cavity can be illuminated in a safe and effective manner, with non-coherent light from a flash-lamp or other suitable source. This illumination can be accomplished in any suitable manner, including by use of a handheld device. Such handheld embodiments may contain a power source (battery or AC), control circuitry, light source (flash-lamp or diode laser), lens (focusing or non-focusing), light filter, and / or fiber-optic for delivering light to the nasal cavity. Embodiments include using any suitable light energy, such as visible light in the red wavelengths with a power output of 1 to 10 Joules per cm2. The device can be pre-programmed to deliver a specified amount of light in a specified amount of time using multiple pulses (in the case of a flash lamp) or a continuous wave (in the case of a diode laser). In many useful embodiments, a rigid fiber-optic extends from the lens / light filter a length of 10 to 20 mm, although it can be any convenient and useful size and shape. Contact sensors can be arrayed on the device for various purposes, such as to restrict illumination to times when the fiber optic is inserted into the nasal cavity. This and / or other safety features can prevent the high-intensity light from being fired into open space, a person's eyes, and / or otherwise causing a potential vision or other hazard. Preferably, the device can be easily and comfortably inserted into a nostril. The fiber-optic can be angled (either in its own shape or by the user manipulating it to a convenient angle / position) so as to allow the user to easily grip the device and insert the fiber-optic without having to use a mirror or other aid. Light from the device can be emitted at a specified light frequency that causes a desired immunosuppressive response in the cellular system.

An extract of prunella spike for treating rheumatoid arthritis and improving immune suppression contains phenolic acid (60-70%) and rosemaric acid (14-21%). Its preparing process is also disclosed.

The invention belongs to the technical field of bioengineering, and particularly relates to a gene-deleted attenuated African swine fever virus strain with innate immune suppression and application. The invention finds that the ASFV MGF-505-7R can inhibit generation of interferon; an ASFV MGF-505-7R gene is deleted in an African swine fever original virulent strain to obtain the attenuated Africanswine fever virus strain with higher safety, thus providing a theoretical basis and practical reference for successful preparation of an African swine fever vaccine in the future. Further, a researchworker can finally prepare safe and effective African swine fever vaccine candidate strains by knocking out the ASFV MGF-505-7R and one or more disclosed virulence genes (such as CD2V, MGF360-12L, MGF360-13L, MGF360-14L, MGF360-505R and the like) simultaneously.

The invention discloses a preparation method and applications of a class of heterocyclic compounds with immunomodulatory effect, specifically a compound with a structure represented by a formula I, wherein various groups are defined in the specification. The invention further provides applications of the compounds in the fields of immunity regulation and PD-1 / PD-L1 inhibition.

Plinabulin and one or more G-CSF drugs are used for treating a chemotherapy induced neutropenia, stimulating neutrophil survival, reducing bone pain induced by the G-CSF drug and alleviating immune suppression effect induced by the G-CSF drug. For example, docetaxel-induced neutropenia can be reduced by-co-administering plinabulin and one or more G-CSF compounds.

Many disorders wherein inflammation is a hallmark such as rheumatoid arthritis, sepsis, or cancer, are chronic and impose a significant burden on family and society due to their high morbidity and mortality. Each year the United States government spends $2.6T to treat chronic Inflammatory diseases, which are linked to 70% of the deaths every year. Protein therapeutics, such as anti-TNFα antibodies that selectively block the TNFα cascade, have become the mainstay therapy for the management of chronic inflammatory diseases. Despite the promise of these early studies, concerns about the side effects of these protein drugs, including induction of auto-antibodies and immuno-suppression, may limit the applications to disease treatments. Thus, there is a need to develop new drugs and delivery systems for the prevention and treatment of inflammatory diseases. The present invention relates to extracellular vesicle composition, system, and methods for treating Toll-like receptor-driven inflammatory disease.

The present invention discloses a method of treating an individual having irritable bowel syndrome or a related disorder, comprising the step of administering to said individual a pharmacologically effective dose of a luminally active anti-inflammatory or immunosuppressive compound with minimal or no systemic side effects. Further provided is a method of inhibiting the onset of symptoms of irritable bowel syndrome or a related disorder in an individual in need of such treatment, comprising the step of administering to the individual a prophylactically effective dose of a luminally active anti-inflammatory or immunosuppressive compound with minimal or no systemic side effects.

Systems and methods to modulate the activation state of immune cells in vivo are described. The systems and methods can be used to transform immunosuppressive macrophages that support cancer growth and metastasis into highly activated tumoricidal macrophages.

Use of dhS1P and / or PhotoImmunoNanoTherapy as a therapeutic agent is described. Administration of therapeutically effective amounts of dhS1P decrease the number of Myeloid Derived Suppressor Cells and immune suppression in cancer patients. Administration of therapeutically effective amounts of dhS1P can be used as an adjuvant to conventional cancer therapies including immunotherapies. Therapeutic results can be achieved by directly administering dhS1P and / or by indirectly increasing the amount of dhS1P at the tumor site. The therapy permits the patient's immune system to recognize and eliminate cancer cells reducing tumor size and extending patient survival.

The present invention provides in certain embodiments compositions comprising at least one CD200 inhibitor, and methods of reversing or modulating immune suppression in a patient having a disease or disorder arising from abnormal cell growth, function or behavior, which method comprises administering to a patient in need thereof a CD200 inhibitor composition.